To prove that MSLN is a therapeutically realistic target for CAR-T cell therapy in AML, the researchers used a xenograft model to show that MSLN CAR-T successfully killed MSLN+ AML cells while also targeting and eliminating CD34+CD38− cells without interfering with the function of normal HSCs. This evidence concerns the gene CD34 and acute myeloid leukemia.